Drugs / Basmisanil
Basmisanil
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT02534207 | Aug → Oct 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02470832 | May → Jul 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02342925 | Feb → May 2015 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02254759 | Oct → Nov 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02194244 | Aug 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01684891 | Sep → Oct 2012 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01667367 | Aug 2012 → Oct 2013 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01436955 | Nov 2011 → Sep 2013 | Down syndrome | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 25 trials · 2 missed | ||||||
| Phase 2 | NCT05307679 | Dec 2022 → Mar 2024 | 15q11q13 microduplication syndrome | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02928393 | Feb → Nov 2017 | stroke disorder | Hoffmann-La Roche | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02953639 | Nov 2016 → Dec 2019 | schizophrenia | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT02484703 | Oct 2015 → Aug 2016 | Down syndrome | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 2 | NCT02024789 | May 2014 → May 2016 | Down syndrome | Hoffmann-La Roche | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Basmisanil | “Basmisanil, a selective GABAA-α5 negative allosteric modulator, was evaluated at 120 mg or 240 mg BID (80 or 160 mg for 12-13 years) in a 6-month, randomized, double-blind,...” PMID 35123401 ↗ Feb 2022 |
| Known as | RG1662 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01436955 ↗ |
| Known as | RO5186582 | “Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics” NCT02953639 ↗ |
| Known as | RO5186582-000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3681419 ↗ |
| Action | Inhibit | “Negative modulation of the GABAA-α5 receptor” PMID 35123401 ↗ Feb 2022 |
| Modality | Small molecule | — CHEMBL3681419 ↗ |
| Route | Oral | “multiple oral doses” NCT01436955 ↗ |